SEC Charges Kiromic BioPharma, 2 Former C-Suite Executives With Misleading Investors About Status of FDA Reviews
December 04, 2024
December 04, 2024
WASHINGTON, Dec. 4 -- The Securities and Exchange Commission issued the following news release:
* * *
SEC declines to impose civil penalties against company due to its self-reporting, remediation, and cooperation.
* * *
The Securities and Exchange Commission today filed settled charges against Houston-based biotherapeutics company Kiromic BioPharma, Inc., its former CEO, Maurizio Chiriva-Internati, and its former chief financial officer, Tony T . . .
* * *
SEC declines to impose civil penalties against company due to its self-reporting, remediation, and cooperation.
* * *
The Securities and Exchange Commission today filed settled charges against Houston-based biotherapeutics company Kiromic BioPharma, Inc., its former CEO, Maurizio Chiriva-Internati, and its former chief financial officer, Tony T . . .